Print this page
-
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Protocol: 082304Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Rectum
Prostate
Small Intestine -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Other Female Genital
Other Male Genital
Urinary Bladder -
A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol: 082401Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Any Site
Ovary
Prostate